Furthermore, the Exo-AAV platform supports conjugation with additional mAbs (e.g., targeting EGFR [81–85], Trop-2 [12–14, 86, 87], NK-1R [88] or MET [89–91]), broadening its applicability to heterogeneous TNBCs and potentially other cancers, such as non-small cell lung cancer. This evidence concerns the gene TACR1 and non-small cell lung carcinoma.